Experimental gene therapy for an in vitro model of proliferative vitreoretinopathy

Canadian Journal of Ophthalmology

Volumn 34, Issue 6-7, 1999, Pages 379-384

  Wong, Christian A ^a   Jia, William ^a   Matsubara, Joanne A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Gene therapy; Herpes simplex virus; Proliferative vitreoretinopathy; Ribonucleotide reductase

Indexed keywords

BETA GALACTOSIDASE; RIBONUCLEOTIDE REDUCTASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DEATH; CELL DIVISION; COMPARATIVE STUDY; ENZYMOLOGY; GENE THERAPY; GENETICS; HERPES SIMPLEX VIRUS 1; LONG EVANS RAT; METHODOLOGY; MUTATION; PATHOLOGY; PIGMENT EPITHELIUM; RAT; VIROLOGY; VITREORETINOPATHY;

ANIMALS; BETA-GALACTOSIDASE; CELL DEATH; CELL DIVISION; CELLS, CULTURED; GENE THERAPY; HERPESVIRUS 1, HUMAN; MUTATION; PIGMENT EPITHELIUM OF EYE; RATS; RATS, LONG-EVANS; RIBONUCLEOTIDE REDUCTASES; VITREORETINOPATHY, PROLIFERATIVE;

EID: 0033255730     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jerdan JA, Pepose JS, Michels RG, Hayashi J, De Bustros S, Sebag M, et al. Proliferative vitreoretinopathy: an immunohistochemical study. Ophthalmology 1989;96: 801-10.
2. Goldstein DJ, Weller SK. Herpes simplex type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988;62: 196-205.
3. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988;166:41-51.
4. Mayerson PL, Hall MO, Clark V, Abrams T. An improved method for isolation and culture of rat retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1985;26: 1599-1609.
5. Wang XF, Cynader MS. Effects of astrocytes on neuronal attachment and survival shown in a serum-free co-culture system. Brain Res Protoc 1999;4:209-16.
6. Nichol PF, Chang JY, Johnson EM Jr, Olivo PD. Herpes simplex virus gene expression in neurons: viral DNA synthesis is a critical regulatory event in the branch point between lytic and latent pathways. J Virol 1996;70: 5476-86.
7. Sakamoto T, Kimura H, Scuric Z, Spee C, Gordon EM, Hinton DR, et al. Inhibition of experimental proliferative vitreoretinopathy by retroviral vector-mediated transfer of suicide gene: Can proliferative vitreoretinopathy be a target of gene therapy? Ophthalmology 1995;102:1417-24.
8. Kimura H, Sakamoto T, Cardillo JA, Spec C, Hinton DR, Gordon EM, et al. Retrovirus-mediated suicide gene transduction in the vitreous cavity of the eye: feasibility in prevention of proliferative vitreoretinopathy. Hum Gene Ther 1996;7:799-808.
9. Wong CA, Potter MJ, Samad A, Chang TS, Ma P, Maberley AL, et al. Human epiretinal membrane cells in an experimental model of PVR in the rabbit [abstract]. Invest Ophthalmol Vis Sci 1996;39:S111.
10. Brandt CR, Imesch P, Spencer B, Eliassi-Rad B, Syed NA, Untawale S, et al. The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. Arch Virol 1997;142:883-96.
11. Yamada Y, Kimura H, Morishima T, Daikodu T, Maeno K. Michiyama Y. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis 1991;164:1091-7.
12. Brandt CR, Kintner RL, Pumfery AM, Visalli RJ, Grau DR. The herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol 1991;72:2043-9.
13. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and replication in mouse cells. Virology 1989;173:276-83.
14. Steiner I. Human herpes viruses latent infection in the nervous system. Immunol Rev 1996;152:157-73.
15. Wang Q, Guo J, Jia W. Intracerebral recombinant HSV-1 does not reactivate latent HSV-1. Gene Ther 1997;4: 1300-4.